The Cost of Imbalance in Clinical Trials / Sylvain Chassang, Rong Feng.
Material type:
- C90
- C93
- I18
- I19
- Hardcopy version available to institutional subscribers
Item type | Home library | Collection | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|---|
Working Paper | Biblioteca Digital | Colección NBER | nber w30745 (Browse shelf(Opens below)) | Not For Loan |
Collection: Colección NBER Close shelf browser (Hides shelf browser)
December 2022.
Clinical trials following the "gold standard" of random assignment frequently use independent lotteries to allocate patients to treatment and control arms. However, independent assignment can generate treatment and control arms that are unbalanced (i.e. treatment and control populations with significantly different demographics), which reduces power. Other assignment methods such as matched pair designs ensure balance across arms while maintaining randomization and permitting inference.
This paper seeks to measure the cost of imbalance with respect to gender in a sample of roughly 2000 clinical studies. We document significant imbalance: 25% of experiments have at least 26% more men in one treatment arm than in the other. In addition, clinical trials with greater imbalance have more dispersed treatment effects, indicating that imbalance reduces the informativeness of experiments. A simple structural model suggests that for a typical experiment, using a balanced random design could deliver informativeness gains equivalent to increasing the sample size by 18%.
Hardcopy version available to institutional subscribers
System requirements: Adobe [Acrobat] Reader required for PDF files.
Mode of access: World Wide Web.
Print version record
There are no comments on this title.